Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks, The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. ... It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos ( PANC )
$PANC Tier Change
Grey Market to Expert Market
Dark or Defunct
Caveat Emptor
Unable to Contact
Company is not able to provide disclosure to the public markets.
Dark or Defunct
Caveat Emptor
Unable to Contact
Volume(Heavy Day)
35,000
January 27, 2020 3:22pm
Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Price $0.001 Day's Change 0.001 (99,900.00%)
[bPanacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
.0013 this looks good to me... To late to buy it now just watch this one Panacos Pharmaceuticals Inc PANC:Grey Market (Common Stock)
breakout on the way http://www.barchart.com/opinions/stocks/PANC
Could Have Ebola Here This story will bring PANC back from the dead..
Up 11% today with no bid and no ask... Get ready something is going to happen...
Good Post..
PANC: Suspended by SEC
http://www.sec.gov/litigation/suspensions/2014/34-71465.pdf
Order:
http://www.sec.gov/litigation/suspensions/2014/34-71465-o.pdf
% Above Low (08/08/13 - 01/02/13)
1,036.36% A very nice move year to date.. They have taken out the bottom.. This is ready for the move up.. With the talk of world pandemic we should see another 1000% move in this one... Best of Luck,,
VERY NICE!!! SOON COMING CHINA EFFECT... LOAD UP... I MAY BE THE ONLY HOLDER IN THE WORLD.... WANT TO SHOOT AT THE MOON BUY WHAT YOU CAN AFFORD TO LOSE... Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.
Balance Sheet
Total Cash (mrq): 26.89M
Total Cash Per Share (mrq): 0.50
Total Debt (mrq): 18.21M
Total Debt/Equity (mrq): 345.33
Current Ratio (mrq): 2.15
Book Value Per Share (mrq): 0.10
Key Executive
Pay
Dr. Alan W. Dunton M.D., 57
Chief Exec. Officer, Pres and Director
637.00K
Panacos trading again 240,000 ....
anybody know what the current float is on PANC?
PANC HOD was .0185
Heavy bids.... PANC looks interesting ..
The news is 3 we have had 3 candle sticks in a row... And 5 cent is not to far away... Looking very good... Or maybe it's ONE because this stock is now in the 1 % percent of all advancing stocks... check the link http://www.barchart.com/snapopinion/stocks/PANC
Seems like she is going higher.
PANC : buyout rumor is unfounded..imo
Wachout for PANC breakout at .018 - .09
could see .025 real quick and then some.
Target could be .04- .06.
volume heavier...would like to see news
That chart does look good... 5 cents looks possible this month..
Accumulation has been very bullish.
You were lucky...was a gift..enjoy it while this moves..you must someoen on your side
; )
Wow i bought on 0,001 for $ 3000,- and today 0,013 on the boards :)
She looks like she wants to go higher for some reason
Would like to hear from the company
PANC - I know that...bought some today.
Is there a specific reason you like them? BIG PHARMA BUYOUT,etc?
Looks good with increasing volume.>Would like to add closer to .01
PANC looking interesting here
YOu still bullish on it?